Developed by HDMA’s Logistics Operations Committee, these guidelines outline steps pharmaceutical supply chain stakeholders can take to protect products while in transit.

The document suggests steps a company could take to analyze in-transit risks; develop and implement an in-transit security strategy suitable to its business to mitigate the identified risks; and, develop a process to audit that strategic effort.